A majority of cardiologists in the Netherlands prescribe ACE inhibitors or beta-blockers for asymptomatic anthracycline-induced cardiac damage in childhood cancer survivors despite a lack of evidence, highlighting the need for randomized controlled trials.
Answers are grounded in this paper and cite their sources.
Current prescribing exceeds evidence for asymptomatic A-CD; leaves open efficacy and supports RCTs before changing practice.
Asymptomatic anthracycline-induced cardiac damage (A-CD) is a serious problem among young childhood cancer survivors. The aim of this survey was to assess the current treatment policy in these patients in the Netherlands. A questionnaire was sent to all 136 departments of adult or pediatric cardiology in the Netherlands. It was returned by 61% of the departments. Sixty-six percent of the respondents started medical treatment (ie, an ACE inhibitor and/or a beta-blocker) in childhood cancer survivors with asymptomatic A-CD. Fifty-eight percent of the respondents indicated that their treatment decision was based on published findings in the literature, but none of them referred to studies evaluating the treatment of asymptomatic A-CD. A majority of adult and pediatric cardiologists started medical treatment in childhood cancer survivors with asymptomatic A-CD without knowledge of the benefits and risks of treatment in this patient group. Before ACE inhibitors and/or beta-blockers can be recommended as routine practice in childhood cancer survivors with asymptomatic A-CD, randomized controlled trials should be performed. Until then, the authors recommend centralizing the treatment of childhood cancer survivors with asymptomatic A-CD in a specialized center to cluster the available knowledge and experience.
No takes yet. Share an insight, caveat, or question.
Dalen et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: